亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Comparison of Pirfenidone and Nintedanib

医学 任天堂 吡非尼酮 肺活量 肺活量测定 冠状动脉疾病 外科 内科学 扩散能力 特发性肺纤维化 肺功能 哮喘
作者
John S. Kim,Susan Murray,Eric Yow,Kevin J. Anstrom,Hyun Joo Kim,Kevin R. Flaherty,Fernando J. Martínez,Imre Noth
出处
期刊:Chest [Elsevier]
被引量:5
标识
DOI:10.1016/j.chest.2023.11.035
摘要

Background

Antifibrotics are effective in slowing FVC decline in idiopathic pulmonary fibrosis (IPF). However, whether antifibrotic type is differentially associated with FVC decline remains inconclusive.

Research Question

Are there significant differences in 12-month FVC decline between pirfenidone and nintedanib?

Study Design and Methods

A post hoc analysis was performed using the CleanUP-IPF trial (No. NCT02759120). Participants who reported using pirfenidone or nintedanib on enrollment into the trial were in the primary analysis. Spirometry was scheduled at baseline and the 12- and 24-month study visits. Linear mixed-effects models with random intercept and slope were used to examine changes in FVC over time. Models were adjusted for age, sex, smoking history, coronary artery disease history, baseline FVC, and 12-month spline term. Survival and nonelective respiratory hospitalization by antifibrotic type were determined using Cox regression models with adjustment for age, sex, smoking history, coronary artery disease history, and baseline FVC and diffusing capacity for carbon monoxide.

Results

Out of the 513 participants with IPF randomized in the CleanUP-IPF trial, 407 reported using pirfenidone (n = 264, 65%) or nintedanib (n = 143, 35%). The pirfenidone group had more participants with a history of coronary artery disease than the nintedanib group (34.1% vs 20.3%, respectively). Patients treated with nintedanib had a higher 12-month visit FVC than patients treated with pirfenidone (mean difference, 106 mL; 95% CI, 34-178). This difference was attenuated at the 24-month study visit. There were no significant differences in overall survival and nonelective respiratory hospitalization between the pirfenidone- and nintedanib-treated groups.

Interpretation

Patients with IPF who used nintedanib had a slower 12-month FVC decline than pirfenidone in a post hoc analysis of a clinical trial.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
生姜批发刘哥完成签到 ,获得积分10
38秒前
大模型应助科研通管家采纳,获得10
1分钟前
英俊的铭应助科研通管家采纳,获得10
1分钟前
1分钟前
Grace发布了新的文献求助10
1分钟前
Hao应助匆匆流浪采纳,获得10
1分钟前
自由冰凡完成签到 ,获得积分10
2分钟前
惜寒完成签到 ,获得积分10
2分钟前
随性随缘随命完成签到 ,获得积分10
2分钟前
2分钟前
华仔应助科研通管家采纳,获得10
3分钟前
3分钟前
Limerencia完成签到,获得积分10
3分钟前
小马甲应助LDHUSH采纳,获得10
3分钟前
ZangXy发布了新的文献求助10
3分钟前
3分钟前
现代元灵完成签到 ,获得积分10
3分钟前
LDHUSH发布了新的文献求助10
3分钟前
3分钟前
火星野花发布了新的文献求助10
4分钟前
烟花应助Grace采纳,获得10
4分钟前
4分钟前
yamo发布了新的文献求助10
4分钟前
科研通AI2S应助外向半青采纳,获得10
4分钟前
ddd完成签到 ,获得积分10
4分钟前
ZangXy完成签到 ,获得积分10
5分钟前
阔达怜雪完成签到 ,获得积分10
5分钟前
5分钟前
脑洞疼应助科研通管家采纳,获得10
5分钟前
7分钟前
nadia发布了新的文献求助30
7分钟前
元谷雪应助自由菠萝采纳,获得10
8分钟前
8分钟前
东方傲儿发布了新的文献求助10
8分钟前
田様应助东方傲儿采纳,获得10
8分钟前
nadia发布了新的文献求助30
8分钟前
外向梨愁完成签到 ,获得积分20
9分钟前
9分钟前
搜集达人应助科研通管家采纳,获得10
9分钟前
oracl完成签到 ,获得积分10
9分钟前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 800
Ethnicities: Media, Health, and Coping 700
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3088490
求助须知:如何正确求助?哪些是违规求助? 2740709
关于积分的说明 7561094
捐赠科研通 2390673
什么是DOI,文献DOI怎么找? 1267954
科研通“疑难数据库(出版商)”最低求助积分说明 613933
版权声明 598648